You searched for "treatment"

832 results found

Movember launches world’s largest cancer real world evidence network

Movember has launched the world’s largest prostate cancer and testicular clinical and research network, aimed at improving the overall survival and quality of life for those living with diseases that affect over 1.4 million men worldwide every year. The leading...

Focal therapies in prostate cancer

The standard of care in the management of prostate cancer has, to date, always been to treat the whole gland. This has ranged from surveillance, surgical excision / prostatectomy or external beam radiotherapy / whole gland brachytherapy. With the evolution...

The Underactive Bladder

For many, a diagnosis of an underactive or atonic bladder represents the end of the line in terms of management options. It remains a poorly understood and even more poorly appreciated condition, both in terms of underlying pathophysiology and alternatives...

An Insider’s Perspective of Prostate Cancer – Understanding Effects, Management Options and Consequences

This deceptively small paperback punches way above its weight compared to some of the existing hefty tomes on prostate cancer. It is an admirable effort at delivering content pitched at both the lay reader as well as the medical graduate....

Role of emergency ureteroscopy in the management of ureteric stones

Emergency ureteroscopy for all acute stone patients is not widespread in the UK but this is not the case elsewhere. In Auckland, New Zealand, it is commonly carried out in the emergency setting to reduce pressure on elective lists and...

Ambulatory local anaesthetic implantation of percutaneous sacral nerve stimulators

Background The current treatment paradigm for detrusor overactivity (DO) and dysfunctional voiding (DV) includes conservative measures, pharmacotherapy, intravesical onabotulinum toxin A (Botox®), sacral nerve modulation (SNM / SNS) and urinary diversion as a last resort [1]. Incidence of DO is...

New ultrasound imaging technique reliably spots prostate cancer, initial patient trial reveals

A groundbreaking new imaging approach developed by researchers at Heriot-Watt University has shown ‘extremely encouraging’ results in early-stage clinical trials on prostate cancer at the Western General Hospital in Edinburgh, Scotland. The ongoing clinical trial demonstrated an initial 94% sensitivity...

Use of MRI in the evaluation of prostate cancer: part 1

Introduction Prostate cancer remains the most commonly diagnosed cancer in males and the second leading cause of cancer related deaths in UK men, after lung cancer [1]. The incidence of prostate cancer in the UK has shown a rapid increase...

Metastatic spinal cord compression – a review

Introduction Metastatic spinal cord compression (MSCC) is an oncological emergency that, unless diagnosed early and treated appropriately, can lead to significant morbidity and mortality, including paralysis and bladder and bowel dysfunction. MSCC can be defined as spinal cord or cauda...

Rishi Sunak joins Prostate Cancer Research as an ambassador

Rishi Sunak with three prostate cancer patients at the Oxford BioDynamics labs. (From left to right: Dafydd Charles, Briane Milne, Rishi Sunak, Alfred Samuels). Former UK Prime Minister Rishi Sunak has joined Prostate Cancer Research as an ambassador, to champion...

Uncovering the fate of small residual fragments

The concept of ‘stone free’ remains an enigma. To some urologists this refers to complete removal of all visible fragments, to others its removal of all ‘clinically significant’ fragments (generally regarded as fragments >2mm), and to some it is absence...

Introduction to prostate cryotherapy

Introduction Cryotherapy was first described by Dr James Arnott in 1850 where he used crushed ice and salt to get temperatures as low as -24oC, in the treatment of cervical and breast tumours [1]. The literature on prostatic cryotherapy dates...